Syncytin 1 antibody orb312961 from Biorbyt | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
Biorbyt for
Syncytin 1 antibody

The Syncytin 1 antibody from Biorbyt is a Rabbit Polyclonal antibody to ERVW-1. This antibody recognizes Homo Sapiens, Human, and Mouse antigen. The Syncytin 1 antibody has been validated for the following applications: EIA, Immunoassay, ELISA, and Western Blot.

Description

Syncytin 1 antibody

Product Specs
ItemSyncytin 1 antibody
CompanyBiorbyt
Price Pricing Info Supplier Page
Catalog Numberorb312961
Quantity50 µl, 100 µl, 200 µl
ApplicationsELISA, WB
Conjugate/TagUnconjugated
ReactivityHuman, Mouse
TargetSyncytin 1
ClonalityPolyclonal
FormatLiquid
ImmunogenKLH conjugated synthetic peptide derived from human Syncytin 1 (451-538/538 aa)
Molecular Weight58 kDa
IsotypeIgG
HostRabbit
Concentration1mg/ml
NCBI Full Gene Nameendogenous retrovirus group W member 1, envelope
NCBI Gene AliasesHERV7Q, HERV-W-ENV, ENVW, ENV, HERVW, HERV-7q, HERVWENV, ERVWE1
StorageShipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles

Specifications/Features

Application Dilutions: WB=1:500-2000, ELISA=1:5000-10000

Add to Compare List

Biorbyt

Biorbyt

7, Signet Court

Swann Road

Cambridge, Cambridgeshire CB5 8LA

United Kingdom

Phone: +44(0)1223 815 212
+44(0)1223 280 240 (fax)
+44(0)1223 280 240

Email: info@biorbyt.com
support@biorbyt.com
accounts@biorbyt.com

Company Profile

Website: https://www.biorbyt.com/

(1) Cytotoxic stress induces transfer of mitochondria-associated human endogenous retroviral RNA and proteins between cancer cellsOncotargetNovember 10, 2017Díaz-Carballo D, Klein J, Acikelli AH, Wilk C, Saka S, Jastrow H, Wennemuth G, Dammann P, Giger-Pabst U, Khosrawipour V, et al.

(2) Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elementsJournal of experimental & clinical cancer research : CRAugust 12, 2015Díaz-Carballo D, Acikelli AH, Klein J, Jastrow H, Dammann P, Wyganowski T, Guemues C, Gustmann S, Bardenheuer W, Malak S, et al.

(3) [Failures, problems and hopes in the transformation of health services. I. Causes of erroneous decisions in the beginning phases of transformation]Casopis lekaru ceskychFebruary 12, 1997Zácek A.

(4) Effect of tumor promoters on sarc gene expression in normal and transformed chick embryo fibroblastsCancer researchApril 1, 1981Pietropaolo C, Laskin JD, Weinstein IB.

Be the First to Write a Review!